Statins reduce risk of liver cancer, death in chronic viral hepatitis
Treatment with certain types of cholesterol-lowering drugs called statins may help reduce the risk of cirrhosis, or irreversible liver scarring, liver cancer, and death in…
Hepatitis
Boosting IRF1 protein prevents growth of hepatitis D virus in study
Increasing the levels of a protein called IRF1 helps suppress infection of the hepatitis D virus (HDV) and its growth inside of cells, a new…
American Liver Foundation gears up for advocacy summit
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
FDA grants fast track status to gene-editing therapy for hepatitis B
The U.S. Food and Drug Administration (FDA) has granted fast track status to PBGENE-HBV, Precision Bioscience’s gene-editing therapy candidate for chronic hepatitis B…
Focus of World Liver Day this April 19 is role of diet in liver health
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
First patient dosed in Phase 3 trial of hepatitis C combination therapy
The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy bemnifosbuvir and ruzasvir in adults with chronic…
Zetomipzomib brings steroid-sparing remission in autoimmune hepatitis
Six months of treatment with Kezar Life Sciences‘ candidate zetomipzomib led to biochemical disease remission for adults with treatment-resistant autoimmune hepatitis, enabling them…
Phase 1 trial of gene-editing therapy for hepatitis B cleared in US
Precision Biosciences has been given the go-ahead to expand a Phase 1 clinical trial testing PBGENE-HBV, its gene-editing therapy for chronic hepatitis…
Phase 3 trial of hepatitis D treatment combo enrolls 1st patient
The first patient has been enrolled in ECLIPSE 1, a Phase 3 clinical trial testing Vir Biotechnology’s experimental combination of tobevibart and elebsiran in adults…
Bemnifosbuvir-ruzasvir Phase 3 trials in hepatitis C launch in April
Atea Pharmaceuticals plans to launch two parallel Phase 3 trials soon to test its investigational combination therapy of bemnifosbuvir and ruzasvir for people with…
Recent Posts
- FDA OKs clinical trials to test cell therapy for chronic hepatitis B
- PBC treatment Ocaliva leaves U.S. market amid safety concerns
- When facing a hospital stay, pack a bag and hope for chocolate cake
- Hormone-like therapy NF-1 shows promise in ICP mouse study
- FDA weighs noninvasive biopsy alternative in MASH clinical trials